These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 32880785)
21. Fluorescent In Situ Hybridization Must be Preferred to pan-TRK Immunohistochemistry to Diagnose NTRK3-rearranged Gastrointestinal Stromal Tumors (GIST). Castillon M; Kammerer-Jacquet SF; Cariou M; Costa S; Conq G; Samaison L; Douet-Guilbert N; Marcorelles P; Doucet L; Uguen A Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):626-634. PubMed ID: 33758144 [TBL] [Abstract][Full Text] [Related]
22. Fine-needle aspiration cytomorphology of papillary thyroid carcinoma with NTRK gene rearrangement from a case series with predominantly indeterminate cytology. Abi-Raad R; Prasad ML; Adeniran AJ; Cai G Cancer Cytopathol; 2020 Nov; 128(11):803-811. PubMed ID: 32931153 [TBL] [Abstract][Full Text] [Related]
23. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma. Su YJ; Lee YH; Jin YT; Hsieh MS Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):264-272. PubMed ID: 35384876 [TBL] [Abstract][Full Text] [Related]
24. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions. Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529 [TBL] [Abstract][Full Text] [Related]
25. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions. Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002 [TBL] [Abstract][Full Text] [Related]
26. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021 [TBL] [Abstract][Full Text] [Related]
27. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma. Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751 [TBL] [Abstract][Full Text] [Related]
28. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors. Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984 [TBL] [Abstract][Full Text] [Related]
29. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Brzeziańska E; Karbownik M; Migdalska-Sek M; Pastuszak-Lewandoska D; Włoch J; Lewiński A Mutat Res; 2006 Jul; 599(1-2):26-35. PubMed ID: 16483615 [TBL] [Abstract][Full Text] [Related]
31. NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC, FISH, RT-PCR, and NGS. Zito Marino F; Buono S; Montella M; Giannatiempo R; Messina F; Casaretta G; Arpino G; Vita G; Fiorentino F; Insabato L; Sgambato A; Orditura M; Franco R; Accardo M J Pathol Clin Res; 2023 Sep; 9(5):367-377. PubMed ID: 37143440 [TBL] [Abstract][Full Text] [Related]
32. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland. Zhang W; Schmitz AA; Kallionpää RE; Perälä M; Pitkänen N; Tukiainen M; Alanne E; Jöhrens K; Schulze-Rath R; Farahmand B; Zong J Acta Oncol; 2024 Jul; 63():542-551. PubMed ID: 38967220 [TBL] [Abstract][Full Text] [Related]
33. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis. Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886 [TBL] [Abstract][Full Text] [Related]
34. NTRK-Rearranged soft tissue neoplasms: A review of evolving diagnostic entities and algorithmic detection methods. Surrey LF; Davis JL Cancer Genet; 2022 Jan; 260-261():6-13. PubMed ID: 34794069 [TBL] [Abstract][Full Text] [Related]
35. Screening for NTRK-rearranged Tumors Using Immunohistochemistry: Comparison of 2 Different pan-TRK Clones in Melanoma Samples. Bourhis A; Redoulez G; Quintin-Roué I; Marcorelles P; Uguen A Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):194-196. PubMed ID: 30920961 [TBL] [Abstract][Full Text] [Related]
36. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes. Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998 [TBL] [Abstract][Full Text] [Related]
37. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report. Wagner F; Greim R; Krebs K; Luebben F; Dimmler A Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873 [TBL] [Abstract][Full Text] [Related]
38. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127 [TBL] [Abstract][Full Text] [Related]
39. Pitfalls in RET Fusion Detection Using Break-Apart FISH Probes in Papillary Thyroid Carcinoma. Liu Y; Wu S; Zhou L; Guo Y; Zeng X J Clin Endocrinol Metab; 2021 Mar; 106(4):1129-1138. PubMed ID: 33382428 [TBL] [Abstract][Full Text] [Related]
40. [Clinicopathological characteristics of NTRK-rearranged mesenchymal tumors in childhood]. Yin MZ; Ma J; He Q; Shen P; Chen JF; Jin XT; Zhang ZD; Kuick CH; Chen HY; Ng EHQ; Aw SJ; Chang KTE Zhonghua Bing Li Xue Za Zhi; 2020 Jul; 49(7):675-680. PubMed ID: 32610377 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]